ArticleScientific reports2018
Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 64 citations in OpenAlex.
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.Archives of toxicology · 2025Review
- Pharmacokinetics of metal excretion following different doses of sodium EDTA infusion.Metallomics : integrated biometal science · 2025Article
- Temporal Assessment of Gadolinium Deposition and T1 Signal Intensity Changes in Rat Kidney with Single and Multiple Doses of Injection: An Experimental Study.The Eurasian journal of medicine · 2024Article
- Investigation of the effect of vitamin K1 prophylaxis on newborn screenings tests in newborns.Journal of medical biochemistry · 2023Article
- Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Article
- Unraveling protein dynamics to understand the brain - the next molecular frontier.Molecular neurodegeneration · 2022Review
- Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.Biomolecules · 2022Review
- Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.Archives of toxicology · 2022Review
- Synthesis and Functionalisation of Superparamagnetic Nano-Rods towards the Treatment of Glioblastoma Brain Tumours.Nanomaterials (Basel, Switzerland) · 2021Article
- Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals.Communications chemistry · 2020Article
- Fibromyalgia associated with repeated gadolinium contrast-enhanced MRI examinations.Radiology case reports · 2020Article
- High-throughput screening for discovery of benchtop separations systems for selected rare earth elements.Communications chemistry · 2020Article
- Recent Advances of Bioresponsive Nano-Sized Contrast Agents for Ultra-High-Field Magnetic Resonance Imaging.Frontiers in chemistry · 2020Review
- Combinatorial design of multimeric chelating peptoids for selective metal coordination.Chemical science · 2019Article
- Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats.Investigative radiology · 2019Article
- Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model.Scientific reports · 2019Article
- Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.Chemical reviews · 2019Review
- Impact of chelation timing on gadolinium deposition in rats after contrast administration.Magnetic resonance imaging · 2019Article
- Evaluating the Patient with Reported Gadolinium-Associated Illness.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several MRI contrast agent clinical formulations are now known to leave deposits of the heavy metal gadolinium in the brain, bones, and other organs of patients. This persistent biological accumulation of gadolinium has been recently recognized as a deleterious outcome in patients administered Gd-based contrast agents (GBCAs) for MRI, prompting the European Medicines Agency to recommend discontinuing the use of over half of the GBCAs currently approved for clinical applications. To address this problem, we find that the orally-available metal decorporation agent 3,4,3-LI(1,2-HOPO) demonstrates superior efficacy at chelating and removing Gd from the body compared to diethylenetriaminepentaacetic acid, a ligand commonly used in the United States in the GBCA Gadopentetate (Magnevist). Using the radiotracer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.